Recce Pharmaceuticals (ASX:RCE) Trading Down 16.4%

Recce Pharmaceuticals Ltd (ASX:RCE) traded down 16.4% on Tuesday . The company traded as low as A$0.23 ($0.16) and last traded at A$0.23 ($0.16), 476,090 shares were traded during mid-day trading. The stock had previously closed at A$0.28 ($0.20).

The firm has a 50 day moving average of A$0.37 and a 200 day moving average of A$0.31. The company has a quick ratio of 7.91, a current ratio of 8.00 and a debt-to-equity ratio of 3.36. The firm has a market cap of $33.89 million and a PE ratio of -8.93.

About Recce Pharmaceuticals (ASX:RCE)

Recce Pharmaceuticals Ltd, a biotechnology company, researches and develops antibiotic drugs in Australia. The company focuses on the development of RECCE 327 that helps to address the problem of antibiotic resistant superbugs. It also develops drugs for the treatment of stomach ulcers and diarrhea. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017.

Read More: When can a hold rating present a buying opportunity?

Receive News & Ratings for Recce Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recce Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.